Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45–56 (2019).
Grupp, S. A., DiNofia, A. M. & Si Lim, S. J. Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Pediatr. Blood Cancer 68, e29123 (2021).
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839–852 (2020).
Brentjens, R. J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9, 279–286 (2003).
Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145–161 (2021).
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361–1365 (2018).
Finck, A. V., Blanchard, T., Roselle, C. P., Golinelli, G. & June, C. H. Engineered cellular immunotherapies in cancer and beyond. Nat. Med. 28, 678–689 (2022).
Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877–884 (2022).
Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545–553 (2020).
Rohaan, M. W. et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 387, 2113–2125 (2022).
Center for Biologics Evaluation and Research (CBER). Approval Letter—Kymriah. U.S. Food and Drug Administration (FDA) https://www.fda.gov/media/106989/download (2017).
Center for Biologics Evaluation and Research (CBER). Approval Letter—Yescarta. U.S. Food and Drug Administration (FDA) https://www.fda.gov/media/108458/download (2017).
Center for Biologics Evaluation and Research (CBER). Approval Letter—Tecartus. U.S. Food and Drug Administration (FDA) https://www.fda.gov/media/140415/download (2020).
Center for Biologics Evaluation and Research (CBER). Approval Letter—Breyanzi. U.S. Food and Drug Administration (FDA) https://www.fda.gov/media/145712/download (2021).
Center for Biologics Evaluation and Research (CBER). Approval Letter—CARVYKTI. U.S. Food and Drug Administration (FDA) https://www.fda.gov/media/156572/download (2022).
Center for Biologics Evaluation and Research (CBER). Approval Letter—ABECMA. U.S. Food and Drug Administration (FDA) https://www.fda.gov/media/147062/download (2021).
Center for Biologics Evaluation and Research (CBER). Approval Letter—Breyanzi. U.S. Food and Drug Administration (FDA) https://www.fda.gov/media/159473/download (2022).
Center for Biologics Evaluation and Research (CBER). Approval letter—Yescarta. U.S. Food and Drug Administration (FDA) https://www.fda.gov/media/157539/download (2022).
Kourelis, T. et al. Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access. J. Clin. Oncol. 40, e20021 (2022).
Al Hadidi, S. et al. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone Marrow Transplant. 58, 443–445 (2023).
Ahmed, N. et al. ‘Waitlist mortality’ is high for myeloma patients with limited access to BCMA therapy. Front. Oncol. 13, 1206715 (2023).
Locke, F. L. et al. Real-world impact of time from leukapheresis to infusion (vein-to-vein time) in patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel. Blood 140, 7512–7515 (2022).
Wang, K. et al. A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies. Cytotherapy 21, 1081–1093 (2019).
Srai, J. S., Badman, C., Krumme, M., Futran, M. & Johnston, C. Future supply chains enabled by continuous processing—opportunities and challenges. May 20–21 2014 Continuous Manufacturing Symposium. J. Pharm. Sci. 104, 840–849 (2015).
Abou-el-Enein, M. et al. Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov. 2, 408–422 (2021).
Levine, B. L., Miskin, J., Wonnacott, K. & Keir, C. Global manufacturing of CAR T cell therapy. Mol. Ther. Methods Clin. Dev. 4, 92–101 (2017).
Myles, L. & Church, T. D. An industry survey of implementation strategies for clinical supply chain management of cell and gene therapies. Cytotherapy 24, 344–355 (2022).
Papathanasiou, M. M. et al. Autologous CAR T-cell therapies supply chain: challenges and opportunities? Cancer Gene Ther. 27, 799–809 (2020).
Harrison, R. P., Ruck, S., Medcalf, N. & Rafiq, Q. A. Decentralized manufacturing of cell and gene therapies: overcoming challenges and identifying opportunities. Cytotherapy 19, 1140–1151 (2017).
Alqazaqi, R. et al. Geographic and racial disparities in access to chimeric antigen receptor-T cells and bispecific antibodies trials for multiple myeloma. JAMA Netw. Open 5, e2228877 (2022).
Palani, H. K. et al. Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India. Bone Marrow Transplant. 58, 160–167 (2022).
Iancu, E. M. & Kandalaft, L. E. Challenges and advantages of cell therapy manufacturing under good manufacturing practices within the hospital setting. Curr. Opin. Biotechnol. 65, 233–241 (2020).
Benjamin, R. et al. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol. 9, e833–e843 (2022).
Benjamin, R. et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet 396, 1885–1894 (2020).
Mailankody, S. et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat. Med. 29, 422–429 (2023).
Neelapu, S. S. et al. First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study. J. Clin. Oncol. 38, 8002 (2020).
Ghassemi, S. et al. Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol. Res. 6, 1100–1109 (2018).
Ottaviano, G. et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci. Transl. Med. 14, eabq3010 (2022).
Chiesa, R. et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N. Engl. J. Med. 389, 899–910 (2023).
Hu, Y. et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 32, 995–1007 (2022).
Lam, C., Meinert, E., Yang, A. & Cui, Z. Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation. Cytotherapy 23, 433–451 (2021).
Ran, T., Eichmüller, S. B., Schmidt, P. & Schlander, M. Cost of decentralized CAR T‐cell production in an academic nonprofit setting. Int. J. Cancer 147, 3438–3445 (2020).
Bersenev, A. & Fesnak, A. Place of academic GMP facilities in modern cell therapy. In Cell Reprogramming for Immunotherapy (eds Katz, S. G. & Rabinovich, P. M.) Vol. 2097, 329–339 (Springer, 2020).
Zhu, F. et al. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy 20, 394–406 (2018).
Mock, U. et al. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy. Cytotherapy 18, 1002–1011 (2016).
Lock, D. et al. Automated, scaled, transposon-based production of CAR T cells. J. Immunother. Cancer 10, e005189 (2022).
Castella, M. et al. Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: experience from an academic phase I clinical trial. Front. Immunol. 11, 482 (2020).
Jackson, Z. et al. Automated manufacture of autologous CD19 CAR-T cells for treatment of non-Hodgkin lymphoma. Front. Immunol. 11, 1941 (2020).
Shah, N. N. et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat. Med. 26, 1569–1575 (2020).
Harrison, R. P., Ruck, S., Rafiq, Q. A. & Medcalf, N. Decentralised manufacturing of cell and gene therapy products: learning from other healthcare sectors. Biotechnol. Adv. 36, 345–357 (2018).
Center for Drug Evaluation and Research (CDER). Distributed Manufacturing and Point-of-Care Manufacturing of Drugs https://www.fda.gov/about-fda/reports-budgets-cder/distributed-manufacturing-and-point-care-manufacturing-drugs-discussion-paper (2022).
Chalasani, R., Hershey, T. B. & Gellad, W. F. Cost and access implications of defining CAR-T therapy as a drug. JAMA Health Forum 1, e200868 (2020).
U.S. Food & Drug Administration (FDA). FDA Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P’s) Product List https://public4.pagefreezer.com/browse/FDA/06-02-2023T10:15/https://www.fda.gov/vaccines-blood-biologics/tissue-tissue-products/fda-regulation-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-product-list (2018).
U.S. Food & Drug Administration (FDA). Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use https://www.fda.gov/media/109176/download (2020).
U.S. Food & Drug Administration (FDA). Same Surgical Procedure Exception under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception https://www.fda.gov/regulatory-information/search-fda-guidance-documents/same-surgical-procedure-exception-under-21-cfr-127115b-questions-and-answers-regarding-scope (2017).
Nagai, S. Regulatory hurdles for CAR T-cell therapy in Japan. Lancet Haematol. 8, e686–e687 (2021).
U.S. Food & Drug Administration (FDA). Identification of Manufacturing Establishments in Applications Submitted to CBER and CDER Questions and Answers https://www.fda.gov/media/131911/download (2019).
U.S. Food & Drug Administration (FDA). Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-Derived Products https://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstration-comparability-human-biological-products-including-therapeutic-biotechnology-derived (1996).
Better, M., Chiruvolu, V. & Sabatino, M. Overcoming challenges for engineered autologous T cell therapies. Cell Gene Ther. Insights 4, 173–186 (2018).
U.S. Food & Drug Administration (FDA). Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products https://www.fda.gov/media/156896/download (2022).
Marks, P. & Gottlieb, S. Balancing safety and innovation for cell-based regenerative medicine. N. Engl. J. Med. 378, 954–959 (2018).
Marks, P. & Gottlieb, S. Statement from FDA Commissioner Scott Gottlieb, M.D. and Peter Marks, M.D., Ph.D., Director of the Center for Biologics Evaluation and Research on New Policies to Advance Development of Safe and Effective Cell and Gene Therapies https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-and-peter-marks-md-phd-director-center-biologics (2019).
Medicines & Healthcare products Regulatory Agency (MHRA). Consultation on Point of Care Manufacturing https://www.gov.uk/government/consultations/point-of-care-consultation/consultation-on-point-of-care-manufacturing (2021).
Nizzi, F. Redefining the role of blood establishments as raw material suppliers, manufacturers, and distributors for new cell therapies: the Blood Systems experience. Transfusion 56, 29S–31S (2016).
Coppens, D. G. et al. Regulating advanced therapy medicinal products through the Hospital Exemption: an analysis of regulatory approaches in nine EU countries. Regen. Med. 15, 2015–2028 (2020).
Coppens, D. G. M. et al. Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries. Cytotherapy 22, 592–600 (2020).
Trias, E., Juan, M., Urbano-Ispizua, A. & Calvo, G. The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001. Bone Marrow Transplant. 57, 156–159 (2022).
Ortíz-Maldonado, V. et al. CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19+ relapsed/refractory malignancies. Mol. Ther. 29, 636–644 (2021).
Therapeutic Goods Administration. Autologous Human Cells and Tissues Products Regulation https://www.tga.gov.au/resources/resource/guidance/autologous-human-cells-and-tissues-products-regulation (2019).
Ivaskiene, T., Mauricas, M. & Ivaska, J. Hospital exemption for advanced therapy medicinal products: issue in application in the European Union Member States. Curr. Stem Cell Res. Ther. 12, 45–51 (2016).
Cuende, N. et al. The puzzling situation of hospital exemption for advanced therapy medicinal products in Europe and stakeholders’ concerns. Cytotherapy 16, 1597–1600 (2014).
The Alliance for Regenerative Medicine. Recommendations for the Use of Hospital Exemption http://alliancerm.org/wp-content/uploads/2020/10/ARM-position-on-HE-final-Oct-2020.pdf (2020).
EFPIA & EBE. Hospital exemption for advanced therapy medicinal products (ATMPs): greater transparency needed in order to improve patient safety and access to ATMPs. https://www.efpia.eu/news-events/the-efpia-view/statements-press-releases/10102017-ebe-and-efpia-call-on-the-eu-commission-and-member-states-to-improve-transparency-on-hospital-exemptions-for-advanced-therapies/ (2017).
Cuende, N. et al. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products. Cytotherapy 24, 686–690 (2022).
Warkentin, P. I. Voluntary accreditation of cellular therapies: Foundation for the Accreditation of Cellular Therapy (FACT). Cytotherapy 5, 299–305 (2003).
Maus, M. V. & Nikiforow, S. The why, what, and how of the new FACT standards for immune effector cells. J. Immunother. Cancer 5, 36 (2017).
Hort, S. et al. Toward rapid, widely available autologous CAR-T cell therapy—artificial intelligence and automation enabling the smart manufacturing hospital. Front. Med. 9, 913287 (2022).
Blache, U., Popp, G., Dünkel, A., Koehl, U. & Fricke, S. Potential solutions for manufacture of CAR T cells in cancer immunotherapy. Nat. Commun. 13, 5225 (2022).
Soler, M. & Lechuga, L. Boosting cancer immunotherapies with optical biosensor nanotechnologies. Eur. Med. J. 4, 124–132 (2019).
Oh, B.-R. et al. Integrated nanoplasmonic sensing for cellular functional immunoanalysis using human blood. ACS Nano 8, 2667–2676 (2014).
Oh, B.-R. et al. Multiplexed nanoplasmonic temporal profiling of T-cell response under immunomodulatory agent exposure. ACS Sens. 1, 941–948 (2016).
Raphael, M. P., Christodoulides, J. A., Delehanty, J. B., Long, J. P. & Byers, J. M. Quantitative imaging of protein secretions from single cells in real time. Biophys. J. 105, 602–608 (2013).
Kurucz, I. et al. Label-free optical biosensor for on-line monitoring the integrated response of human B cells upon the engagement of stimulatory and inhibitory immune receptors. Sens. Actuators B Chem. 240, 528–535 (2017).
Soler, M. et al. Two-dimensional label-free affinity analysis of tumor-specific CD8 T cells with a biomimetic plasmonic sensor. ACS Sens. 3, 2286–2295 (2018).
Walsh, A. J. et al. Classification of T-cell activation via autofluorescence lifetime imaging. Nat. Biomed. Eng. 5, 77–88 (2020).
Rossoff, J. et al. Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. Blood 138, 2138–2142 (2021).
Jacobson, C. A. et al. Outcomes of patients (Pts) in ZUMA-9, a multicenter, open-label study of axicabtagene ciloleucel (axi-cel) in relapsed/refractory large B cell lymphoma (R/R LBCL) for expanded access and commercial out-of-specification (OOS) product. Blood 136, 2–3 (2020).
Chong, E. A. et al. CAR T cell viability release testing and clinical outcomes: is there a lower limit? Blood 134, 1873–1875 (2019).
U.S. Food & Drug Administration (FDA). Approval Order—CliniMACS CD34 Reagent System https://wayback.archive-it.org/7993/20190208123839/https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/ucm382986.htm (2014).
U.S. Food & Drug Administration (FDA). Getting a Humanitarian Use Device to Market https://www.fda.gov/medical-devices/humanitarian-device-exemption/getting-humanitarian-use-device-market (2022).
Priesner, C. et al. Automated enrichment, transduction, and expansion of clinical-scale CD62L+ T cells for manufacturing of gene therapy medicinal products. Hum. Gene Ther. 27, 860–869 (2016).
Lock, D. et al. Automated manufacturing of potent CD20-directed chimeric antigen receptor T cells for clinical use. Hum. Gene Ther. 28, 914–925 (2017).
Blaeschke, F. et al. Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia. Cancer Immunol. Immunother. 67, 1053–1066 (2018).
Castella, M. et al. Development of a novel anti-CD19 chimeric antigen receptor: a paradigm for an affordable CAR T cell production at academic institutions. Mol. Ther. Methods Clin. Dev. 12, 134–144 (2019).
Zhang, W., Jordan, K. R., Schulte, B. & Purev, E. Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system. Drug Des. Devel. Ther. 12, 3343–3356 (2018).
Aleksandrova, K. et al. Functionality and cell senescence of CD4/ CD8-selected CD20 CAR T cells manufactured using the automated CliniMACS Prodigy® platform. Transfus. Med. Hemother. 46, 47–54 (2019).
Fernández, L. et al. GMP-compliant manufacturing of NKG2D CAR memory T cells using CliniMACS Prodigy. Front. Immunol. 10, 2361 (2019).
Vedvyas, Y. et al. Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Sci. Rep. 9, 10634 (2019).
Arcangeli, S. et al. Next-generation manufacturing protocols enriching TSCM CAR T cells can overcome disease-specific T cell defects in cancer patients. Front. Immunol. 11, 1217 (2020).
Bozza, M. et al. A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells. Sci. Adv. 7, eabf1333 (2021).
Palen, K., Zurko, J., Johnson, B. D., Hari, P. & Shah, N. N. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model? Cytotherapy 23, 985–990 (2021).
Glienke, W. et al. GMP-compliant manufacturing of TRUCKs: CAR T cells targeting GD2 and releasing inducible IL-18. Front. Immunol. 13, 839783 (2022).
Joedicke, J. J. et al. Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages. Mol. Ther. Methods Clin. Dev. 24, 181–198 (2022).
Nicod, C. et al. CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans. Curr. Res. Transl. Med. 71, 103385 (2023).
Maschan, M. et al. Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nat. Commun. 12, 7200 (2021).